Banque Pictet & Cie SA decreased its holdings in Astrazeneca PLC (NYSE:AZN) by 0.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 267,899 shares of the company’s stock after selling 1,548 shares during the period. Banque Pictet & Cie SA’s holdings in Astrazeneca PLC were worth $17,810,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also bought and sold shares of the company. Meeder Asset Management Inc. acquired a new position in shares of Astrazeneca PLC during the second quarter worth $105,000. WFG Advisors LP grew its stake in shares of Astrazeneca PLC by 36.0% during the second quarter. WFG Advisors LP now owns 3,716 shares of the company’s stock worth $127,000 after purchasing an additional 984 shares in the last quarter. Bronfman E.L. Rothschild L.P. grew its stake in shares of Astrazeneca PLC by 71.2% during the second quarter. Bronfman E.L. Rothschild L.P. now owns 4,252 shares of the company’s stock worth $145,000 after purchasing an additional 1,769 shares in the last quarter. Quadrant Capital Group LLC grew its stake in shares of Astrazeneca PLC by 18.4% during the second quarter. Quadrant Capital Group LLC now owns 5,437 shares of the company’s stock worth $147,000 after purchasing an additional 846 shares in the last quarter. Finally, Westport Asset Management Inc. acquired a new position in shares of Astrazeneca PLC during the second quarter worth $170,000. Institutional investors and hedge funds own 14.16% of the company’s stock.

Astrazeneca PLC (NYSE:AZN) traded up $0.13 during mid-day trading on Friday, hitting $33.52. 1,991,200 shares of the stock traded hands, compared to its average volume of 4,816,348. The firm has a market capitalization of $83,360.00, a price-to-earnings ratio of 7.97, a PEG ratio of 3.15 and a beta of 0.79. Astrazeneca PLC has a twelve month low of $25.55 and a twelve month high of $35.60. The company has a quick ratio of 0.72, a current ratio of 0.94 and a debt-to-equity ratio of 1.09.

Astrazeneca PLC (NYSE:AZN) last released its quarterly earnings results on Thursday, November 9th. The company reported $1.12 EPS for the quarter, beating the consensus estimate of $0.57 by $0.55. The business had revenue of $6.23 billion for the quarter, compared to analyst estimates of $6 billion. Astrazeneca PLC had a net margin of 15.90% and a return on equity of 34.02%. The company’s quarterly revenue was up 9.4% on a year-over-year basis. During the same period in the prior year, the business earned $1.32 earnings per share. sell-side analysts expect that Astrazeneca PLC will post 1.93 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This article was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this article on another website, it was illegally copied and republished in violation of U.S. and international copyright and trademark law. The original version of this article can be accessed at https://www.dailypolitical.com/2017/11/17/banque-pictet-cie-sa-reduces-holdings-in-astrazeneca-plc-azn.html.

Several equities analysts have issued reports on the stock. BMO Capital Markets set a $38.00 price objective on shares of Astrazeneca PLC and gave the company a “buy” rating in a research note on Wednesday. Leerink Swann upped their price objective on shares of Astrazeneca PLC from $31.00 to $34.00 and gave the company a “market perform” rating in a research note on Monday, October 23rd. Citigroup Inc. upgraded shares of Astrazeneca PLC to a “buy” rating in a research note on Wednesday, October 18th. Cowen and Company restated a “hold” rating and issued a $37.00 price objective on shares of Astrazeneca PLC in a research note on Tuesday, October 17th. Finally, Credit Suisse Group raised shares of Astrazeneca PLC from a “neutral” rating to an “outperform” rating in a report on Monday, October 16th. Four research analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $34.20.

About Astrazeneca PLC

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Institutional Ownership by Quarter for Astrazeneca PLC (NYSE:AZN)

Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.